FPF
PRTK

FNY Partners Fund’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

FNY Partners Fund’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-945
Closed -$23K – 645
2017
Q3 		$23K Buy
+945
New +$22K ﹤0.01% 364

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

FNY Partners Fund's PRTK Position: Q4 2017 in Review

FNY Partners Fund sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 40,700 shares — an estimated $1.02M sold.

FNY Partners Fund first reported a position in PRTK in Q3 2017 and held it in 1 quarter. The position peaked at $1.02M in Q3 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • FNY Partners Fund reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • FNY Partners Fund sold 40,700 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.02M.
  • FNY Partners Fund first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • FNY Partners Fund's Paratek Pharmaceuticals, Inc. position peaked at $1.02M in Q3 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on FNY Partners Fund's 13F filing for Q4 2017, filed 24 Jan 2018.